Ionis Pharmaceuticals (IONS) Q4 2025 earnings summary

Executive summary

• Achieved strong commercial and clinical momentum with four approved medicines, including two successful independent product launches (TRYNGOLZA for FCS and DAWNZERA for HAE), and multiple positive phase 3 data readouts across the pipeline.

• Exceeded 2025 revenue guidance, driven by robust product sales, expanding commercial execution, and pipeline progress.

• Multiple launches planned for 2025–2027, including first-in-class and blockbuster candidates such as Olezarsen for sHTG and Zilganersen for Alexander disease.

• Transitioned to a fully integrated commercial-stage company with accelerating revenue growth and a clear path to cash flow breakeven by 2028.

Financial highlights

• 2025 revenue reached $944 million, a 34% year-over-year increase, with $436 million from commercial products and $508 million from R&D collaborations.

• TRYNGOLZA generated $108 million in product sales in its first year, with Q4 sales of $50 million (56% quarter-over-quarter growth).

• DAWNZERA contributed $8 million in initial product sales, with strong free trial conversion and $7 million in Q4 2025.

• Royalty revenues rose 11% to $285 million, driven by Spinraza and Waylivra; SPINRAZA and WAINUA royalties totaled $212 million and $49 million, respectively.

• Non-GAAP operating loss for 2025 was $248 million, with 2026 projected at $500–$550 million, similar to 2025 when excluding one-time items.

Outlook and guidance

• 2026 revenue guidance of $800–$825 million, representing ~20% growth after adjusting for a one-time license fee.

• Guidance assumes standard review for Olezarsen, with sHTG approval and launch expected in Q4; priority review could improve outlook.

• Expects DAWNZERA sales to grow steadily as launch progresses, with peak sales potential over $500 million.

• Projects to end 2026 with $1.6 billion in cash and investments, after repaying $433 million in convertible notes.

• Plans to achieve cash flow breakeven in 2028 and sustainable positive cash flow thereafter.